Why GLP-1 users are turning to CGM
Ozempic labeling describes glucose-dependent insulin secretion, reduced glucagon and delayed gastric emptying. CGM provides glucose observations, not a direct measure of insulin sensitivity or independent proof of medication efficacy.
In studied adults with type 2 diabetes, semaglutide lowers fasting and postprandial glucose. A personal CGM change does not isolate the medication’s effect or prove the mechanism.
CGM can supply glucose observations for discussion with your prescriber, but a personal trace does not establish medication efficacy, dose adequacy or the cause of a change. Do not adjust or switch medication from sensor data; follow the prescribed plan.
For Type 2 diabetes users: if you're on Ozempic for blood sugar management, CGM can provide day-to-day data between laboratory HbA1c checks, and you can see how different meals affect your glucose on GLP-1s. Whether a device can warn you of low blood sugar before symptoms depends on the system: prescription systems such as the Dexcom G7 offer customizable low-glucose alerts, while the over-the-counter Dexcom Stelo does not include clinical low-glucose alarms. Ask your prescriber which CGM suits your treatment.
If you use insulin alongside your GLP-1 medication, you need a prescription CGM (Dexcom G7 or FreeStyle Libre 3) — not an OTC device. OTC CGMs are not cleared for insulin dosing decisions. Talk to your prescriber.
What CGM reveals on GLP-1 medications
Ozempic labeling reports lower fasting and postprandial glucose in studied adults with type 2 diabetes. An individual’s CGM pattern can vary and does not establish the cause of a change or medication efficacy.
Ozempic labeling describes reduced fasting and postprandial glucose in adults with type 2 diabetes. Responses vary and a CGM curve does not measure insulin sensitivity.
Sensor variability does not establish changes in mood, hunger or energy. Discuss symptoms and glucose observations with your prescriber.
CGM shows interstitial glucose alongside logged events. Associations in one person’s trace do not prove a meal, activity, sleep or stress caused the change. Glucose alone does not measure insulin, fat burning, energy availability or overall metabolic health.
Best CGM devices for GLP-1 users
Not on insulin — OTC labeling and suitability:
Dexcom Stelo is an over-the-counter device for people aged 2 years and older who do not use insulin, with caregiver supervision below 18. It is not intended for problematic hypoglycemia or dialysis and has no clinical high/low alarms. Platform enrollment may have narrower eligibility. Semaglutide labeling warns of increased hypoglycemia risk with insulin or sulfonylureas. Not using insulin alone does not establish that an OTC device without clinical low-glucose alarms is suitable. Discuss medication risks and device selection with your prescriber. Read our review →
Nutrisense currently lists Dexcom Stelo among its products. Coaching plans provide access to registered dietitians. Check the selected plan for sensor quantity, coaching and service eligibility; the device’s FDA indication does not determine eligibility for the service. Coaching is not a medication-efficacy test. Read our review →
On insulin — prescription required:
Original Libre 3 is a prescription CGM; discuss suitability and plan-specific coverage with your care team. Read our review →
Do you need a prescription CGM on Ozempic?
If using insulin, select a suitably cleared prescription CGM with your prescriber. Coverage requires all applicable plan criteria.
Semaglutide labeling warns of increased hypoglycemia risk with insulin or sulfonylureas. Not using insulin alone does not establish that an OTC device without clinical low-glucose alarms is suitable. Discuss medication risks and device selection with your prescriber. Dexcom Stelo is an over-the-counter device for people aged 2 years and older who do not use insulin, with caregiver supervision below 18. It is not intended for problematic hypoglycemia or dialysis and has no clinical high/low alarms. Platform enrollment may have narrower eligibility.
Coverage depends on the exact device, plan, documentation and supplier. Medicare requires all applicable criteria, including diabetes, a prescription, training, FDA-consistent use, required visits and insulin treatment or documented problematic hypoglycemia. Ask your insurer and prescriber about your situation.